Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17082114 | 0.92 | CRBN (0.48) | CRBNPDE7ATRPV1MAPTDDB1 | |
| SCHEMBL4570142 | 0.92 | CRBN (0.48) | CRBNPDE7ATRPV1MAPTDDB1 | |
| SCHEMBL10112720 | 0.91 | DGAT1 (0.43) | CRBNPDE7ATRPV1MAPTRAB9A | |
| SCHEMBL10112739 | 0.89 | SMN1; SMN2 (0.41) | CRBNPDE7ATRPV1MAPTKDM4E | |
| SCHEMBL4720617 | 0.89 | CRBN (0.45) | CRBNPDE7ATRPV1MAPTKDM4E | |
| SCHEMBL4826982 | 0.89 | CRBN (0.45) | CRBNPDE7ATRPV1MAPTKDM4E | |
| SCHEMBL10112722 | 0.87 | CRBN (0.39) | CRBNPDE7ATRPV1MAPTKDM4E | |
| SCHEMBL9101854 | 0.83 | PDE7A (0.42) | CRBNPDE7ATRPV1MAPTKDM4E | |
| SCHEMBL4570143 | 0.83 | CRBN (0.45) | CRBNPDE7ATRPV1MAPTDDB1 | |
| SCHEMBL17082009 | 0.83 | CRBN (0.45) | CRBNPDE7ATRPV1MAPTDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | CRBN 2523/4885PDE7A 655/4885TRPV1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.